TY - JOUR
T1 - AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper
AU - Turner, Michelle C
AU - Radzikowska, Urszula
AU - Ferastraoaru, Denisa E
AU - Pascal, Mariona
AU - Wesseling, Pieter
AU - McCraw, Alexandra
AU - Backes, Claudine
AU - Bax, Heather J
AU - Bergmann, Christoph
AU - Bianchini, Rodolfo
AU - Cari, Luigi
AU - de Las Vecillas, Leticia
AU - Izquierdo, Elena
AU - Lind-Holm Mogensen, Frida
AU - Michelucci, Alessandro
AU - Nazarov, Petr V
AU - Niclou, Simone P
AU - Nocentini, Giuseppe
AU - Ollert, Markus
AU - Preusser, Matthias
AU - Rohr-Udilova, Nataliya
AU - Scafidi, Andrea
AU - Toth, Reka
AU - Van Hemelrijck, Mieke
AU - Weller, Michael
AU - Jappe, Uta
AU - Escribese, Maria M
AU - Jensen-Jarolim, Erika
AU - Karagiannis, Sophia N
AU - Poli, Aurélie
N1 - Funding Information:
All authors have read and approved the Position Paper. AMC, AM, AP, AS, ClB, DF; FLM, EI, GN, LC, LV, MCT, MPa, MO, MVH, MW, NRU, SPN, PVN, PW, RT, RB and UR declare no conflict of interest. CB received honoraria for presentations from Allergy Therapeutics, Bencard, HAL Allergy and SCS. EJJ declares inventorship in patents on allergen immunotherapy formulation with Biomedical International R+D, Vienna, Austria, of which she is a shareholder. She received honoraria for presentations from Allergy Therapeutics, AllergoPharma, Bencard, Meda, Roxall, ThermoFisher, and consulted previously for MediGene, Germany, Novartis, for Allergy Therapeutics and Dr. Schär. MME has received honoraria from lectures from the following companies: Stallegenes Greer, Diater and GSK. MPr has received honoraria for lectures, consultation or advisory board participation from the following for‐profit companies: Bayer, Bristol‐Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier. SNK is founder and shareholder of Epsilogen Ltd. (formerly IGEM Therapeutics Ltd.) and has received funds from IGEM Therapeutics Ltd/Epsilogen Ltd. HJB is employed through a fund provided by Epsilogen Ltd. SNK and HJB are inventors of patents on antibody technologies. AJM is supported by the UK Medical Research Council (MR/R015643/1) and King's College London member of the MRC Doctoral Training Partnership in Biomedical Sciences. UJ has received a hotel accommodation and catering for a lecture and chairing of a workshop organized by ALK Abello. The honorarium went to her institution, the RCB. Her research on molecular allergology is funded by the Federal Ministry of Education and Science, the Federal Ministries of Technology, Economy and Technology, Food and Agriculture (BMEL), the German Research Foundation and the Kanert Foundation. MW has received research grants from Quercis and Versameb, and honoraria for lectures or advisory board participation or consulting from Bayer, Curevac, Medac, Novartis, Novocure, Orbus, Philogen, Roche and Sandoz.
Funding Information:
AP/AS is financially supported by the Action Lions Vaincre le Cancer association. AP is supported by FNRS‐Télévie (PDR‐TLV 2023 RESTAGE). FLM is supported by the Luxembourg National Research Fund (FNR) through the FNR‐PRIDE program i2TRON for doctoral education (PRIDE/14254520/I2TRON). MCT is funded by a Ramón y Cajal fellowship (RYC‐2017‐01892) from the Spanish Ministry of Science, Innovation and Universities and co‐funded by the European Social Fund. ISGlobal acknowledges support from the grant CEX2018‐000806‐S funded by MCIN/AEI/ 10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. MME has projects funded by Fundación Mutua Madrileña, Grant/ Award Number: AP177712021; Ministerio de Ciencia, Innovación y Universidades, Grant/Award Number: PCI2018‐092930; Instituto de Salud Carlos III‐European Regional Development Fund, Grant/Award Number: RD16/0006/0015, RD21/0002/0008. SNK has projects supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS‐BRC‐1215‐20006); the Medical Research Council (MR/L023091/1, MR/V049445/1, MR/R015643/1), the Biotechnology and Biological Sciences Research Council (BB/T008709/1); Breast Cancer Now (147; KCL‐BCN‐Q3); the Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135); The Guy's and St Thomas's Foundation Trust Charity (Melanoma Special Fund, 573); Innovate UK (463087); the British Skin Foundation (006/R/22); Cancer Research UK (C30122/A11527; C30122/A15774). UJ has projects funded by the German Research Foundation (DFG) (JA 1007/2‐3), the Federal Ministry of Education and Science (BMBF) (DZL and INDICATE‐FH), and the Federal Ministry of Food and Agriculture (BMEL) (AptaSens).
Funding Information:
The Task Force named “AllergoOncology in the Era of Personalized, Stratified, and Precision Medicine” (STRATALLON) of the Working Group AllergoOncology was supported by the European Academy for Allergy and Clinical Immunology (EAACI). The authors would like to thank EAACI for its financial support in the development of this position paper. The writing of this position paper was undertaken by representatives from EAACI and the European Association of Neuro‐Oncology (EANO), who collaborated under a Memorandum of Understanding.
Publisher Copyright:
© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2024/6
Y1 - 2024/6
N2 - Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.
AB - Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.
UR - http://www.scopus.com/inward/record.url?scp=85183058054&partnerID=8YFLogxK
U2 - 10.1111/all.15994
DO - 10.1111/all.15994
M3 - Article
C2 - 38263898
SN - 0105-4538
VL - 79
SP - 1419
EP - 1439
JO - Allergy
JF - Allergy
IS - 6
ER -
